Paul Hastings
2013 - OncoMed Pharmaceuticals
In 2013, Paul Hastings earned a total compensation of $2.5M as Chairman, Chief Executive Officer & President at OncoMed Pharmaceuticals, a 339% increase compared to previous year.
Compensation breakdown
| Bonus | $175,000 |
|---|---|
| Non-Equity Incentive Plan | $163,298 |
| Option Awards | $1,707,944 |
| Salary | $453,604 |
| Total | $2,499,846 |
Hastings received $1.7M in option awards, accounting for 68% of the total pay in 2013.
Hastings also received $175K in bonus, $163.3K in non-equity incentive plan and $453.6K in salary.
Rankings
In 2013, Paul Hastings' compensation ranked 3,130th out of 12,286 executives tracked by ExecPay. In other words, Hastings earned more than 74.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,130 out of 12,286 | 75th |
Division Manufacturing | 1,058 out of 4,612 | 77th |
Major group Chemicals And Allied Products | 276 out of 1,462 | 81st |
Industry group Drugs | 188 out of 1,156 | 84th |
Industry Pharmaceutical Preparations | 156 out of 890 | 83rd |
Source: SEC filing on April 24, 2015.
Hastings' colleagues
We found two more compensation records of executives who worked with Paul Hastings at OncoMed Pharmaceuticals in 2013.